Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

EMA HQ Heads to Amsterdam

By Ryan Bushey | November 21, 2017

Europe’s top agency for evaluating medical products has found a new home.

The European Medicines Agency (EMA) will relocate to Amsterdam in the Netherlands. It now has over 16 months to prepare for the move and set up operations there by March 30th, 2019 at the latest, which is the date Britain will finalize its exit from the European Union.

“Amsterdam ticks many of our boxes, said EMA Executive Director Guido Rasi, in a statement.

“It offers excellent connectivity and a building that can be shaped according to our needs. I am very grateful that the Member States took into account our requirements for business continuity and gave priority to the protection of public and animal health.”

Nineteen countries were in competition to become the EMA’s new home, according to Science. Cities produced videos and websites highlighting elements like their international connections, quality of life, and international schools.

However, the final decision came down to votes cast by the ministers of the 27 countries that remain in the European Union. Each country had six votes in the first round of process. Three votes went to the city of first choice, two to the second, and one to the third. Two rounds of voting led Amsterdam and Milan to the last round, which ended in a tie.

The tie was broken when both cities’ names were placed in a bowl with Amsterdam being the final pick.

Pharmaceutical and patient groups welcomed the announcement the agency would move to Amsterdam, reported Politico. These groups had previously called for a seamless transition to ensure the drug approval process across the EU would not be affected.

Construction of the building should be completed by April 2019 with the facility expected to be custom-built for the EMA’s needs.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50